Soleo Communications

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR (diazoxide choline controlled-release), is a once-daily oral tablet being developed for the treatment of Prader-Willi Syndrome (PWS). DCCR has received Orphan Drug designation in both the U.S. and EU, as well as Fast Track designation from the FDA. Following positive results from its Phase 3 clinical program, the company is currently progressing toward regulatory submission and potential commercialization. Soleno's mission is to address significant unmet medical needs in orphan indications through targeted therapeutic interventions.